Breakthrough Autism Drug ART-501 Positive in Phase 2 Trial
Four of six adults with autism spectrum disorder in a Phase 2a pilot study showed signs of clinical benefit...
Bioatla Inks Sizable $22.5M Flexible Financing Agreement
BioAtla secured $7.5 million in near-term liquidity via pre-paid advance agreements and added a $15 million standby equity line...
FDA Accepts BLA Submission for ST-920 Fabry Disease Drug
In the Phase 1/2 STAAR study, isaralgagene civaparvovec (ST-920) generated a positive mean annualized eGFR slope at 52 weeks...
New Babesiosis Study Site Open for Enrollment at Mount Sinai
Phase 2 B-FREE will test a 12‑week tafenoquine regimen in up to 100 patients with chronic babesiosis, measuring change...
Cartesian’s SLE Trial Shows Strong Efficacy for Descartes-08
In an open-label Phase 2 study of systemic lupus erythematosus, Descartes-08 produced a 100% LLDAS response at Month 3...
Eupraxia’s EoE Drug Delivers Consistent Results at 52 Weeks
At 52 weeks, 2 of 3 patients in Cohort 6 of Eupraxia’s RESOLVE trial remained in clinical remission on...
Celcuity Submits New Breast Cancer Drug Application to FDA
The Phase 3 VIKTORIA-1 PIK3CA wild-type cohort reported a hazard ratio of 0.24 for the gedatolisib triplet (gedatolisib, fulvestrant,...
Pasithea’s NF1 Drug PAS-004 Shows Positive PK Data in Trial
PAS-004’s new tablet showed linear, dose-proportional PK with a long half-life (~57 hours) and tight peak–trough control at steady...
New Data Highlights Zio Performance in an Asian Population
In a real-world analysis of 408,470 U.S. patients monitored with iRhythm’s Zio long-term continuous ECG service, median wear time...
Annovis Links Amyloid to Faster Decline in Parkinson’s
Annovis reported that in its Phase 3 study in early Parkinson’s disease (NCT05357989), buntanetap halted cognitive decline across the...